Ind-Swift Laboratories Limited — Others, 14-08-2025: Monitoring Agency Report

Ind-Swift Laboratories' Monitoring Agency Report for the quarter ending June 30, 2025, on its Rs 314.60 Cr preferential issue, indicates Rs 22.42 Cr remains unutilized. While funds were largely used as stated, the agency noted commingling with other company funds, which Ind-Swift attributes to operational efficiency. A critical point for investors is the current share price (Rs 103.60) below the warrant exercise price (Rs 121.00), potentially affecting future conversions. The company recently completed a major business shift by selling its API and CRAMS divisions and merging with its formulations group company, significantly altering its operational profile.